GLP-1 use for weight loss increases the suicide rate by 150%
Ozempic's Dark Side: 45% Increased Risk of Suicidal Ideation
Summary by Glasp - Claude AI - June 2026
The article's headline finding draws on a JAMA Network Open analysis of WHO data reporting a 45% increased risk of suicidal ideation in patients taking semaglutide compared to other medications. For patients also on antidepressants or antianxiety medications, it cites a 150% to 300% increase in suicidal ideation among that subgroup.
Supporting evidence cited
The piece stacks several pharmacovigilance (adverse-event database) studies:
- A study of 209,354 adverse event reports for these medications, finding a troubling association with suicidal thoughts and self-harm, with higher rates for liraglutide, semaglutide, and tirzepatide.
- A European Pharmacovigilance Database analysis: Out of 41,236 adverse event reports for these drugs, 230 involved suicidal events, with newer high-dose weight-loss formulations showing two to four times higher odds of suicidal event reports compared to older GLP-1 drugs.
- A EudraVigilance analysis where Out of 31,444 total adverse event reports, 372 (1.18%) were related to psychiatric issues, led by depression (50.3%), anxiety (38.7%), and suicidal ideation (19.6%).
Proposed mechanism
The article argues GLP-1 receptors exist in brain regions governing mood and reward, and that the drugs may increase dopamine transporter expression, reducing free dopamine levels in certain brain areas, plus possibly act via the hypothalamic-pituitary-adrenal axis. It includes individual case reports and user testimonials of depression/anxiety that resolved on discontinuation.
Other harms section
Beyond psychiatric effects, it links the drugs to gastroparesis/stomach paralysis, pancreatitis, bowel obstruction (increases the rate of intestinal obstruction by 3.5-fold), "Ozempic face/breast/butt," and NAION (a rare optic neuropathy), citing a pooled hazard ratio of 2.81 and a Harvard study with hazard ratios of 4.28–7.64.
The pitch
The closing two-thirds pivots to promoting Akkermansia muciniphila probiotics as a "natural alternative" to raise GLP-1 endogenously, with extended detail on dosing, CFU/AFU/TFU metrics, and mitochondrial/seed-oil preparation—alongside book and product promotions.
Nearly all the "suicide" evidence here is disproportionality/adverse-event-reporting data, which establishes association and signal, not causation—and the article itself repeatedly concedes the absolute numbers are low. Notably, larger cohort and pharmacoepidemiologic studies (and the EMA's 2024 review conclusion) have generally not confirmed a causal suicidality signal, which this piece doesn't mention. The Akkermansia "alternative" framing rests largely on mouse data plus a vendor-CEO interview, and the GLP-1-elevation claims for the probiotic are far weaker than the pharmacological effect it's positioned against. The confounding-by-indication point the article briefly raises (obesity and diabetes independently elevate suicide risk) cuts against its own thesis more than it acknowledges.
Related in VitaminDWiki
- Vitamin D, Omega-3, Butyrate etc., should help if taking GLP-1 for weight loss
- The Potential Synergy Between Vitamin D and GLP-1 Medications for Enhanced Weight Loss
_GLP-1 reduces Vitamin D, Low Vitamin D increases Suicide risk
- From Claude AI: "Research shows GLP-1 users face a 49% higher risk of vitamin D deficiency compared to other diabetes medications."
- Suicide associated with low vitamin D - many studies
- Suicide 2X more likely with low vitamin D (in military)
- Suicide 4X more likely if have Restless Legs Syndrome (perhaps low vitamin D or Magnesium)